This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
The #NephJC editorial on PATH-BP is now live on Kidney Medicine!
Nice work by Momen Abbasi, Priya John, Cristina Popa, helmed by Jade and Jamie.
The PATH-BP trial dropped - check out the results and the take from the #NephJC chats (in an <2 min summary)
This weeks #TenTweetNephJC makes us sad - does taking regular acetaminophen (paracetamol) cause hypertension?
— Nephrology Jrnl Club (@NephJC) March 13, 2022
Find out below in this rapid review of the Scottish trial, as we catch up on the #NephJC take on things 👇 pic.twitter.com/MaPBgApmBU
Excellent visual abstract from Husam Alzayer, NSMC intern of the class of 2022
